Activation of Serum Response Factor by RhoA Is Mediated by the Nuclear Factor-kappa B and C/EBP Transcription Factors*

Silvia MontanerDagger §, Rosario PeronaDagger , Luisa Saniger, and Juan Carlos Lacalparallel

From the Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas, Madrid, Spain

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The activity of the transcription factor NF-kappa B can be modulated by members of the Rho family of small GTPases (Perona, R., Montaner, S., Saniger, L., Sánchez-Pérez, I., Bravo, R., and Lacal, J. C. (1997) Genes Dev. 11, 463-475). Ectopic expression of RhoA, Rac1, and Cdc42Hs proteins induces the translocation of NF-kappa B dimers to the nucleus, triggering the transactivation of the NF-kappa B-dependent promoter from the human immunodeficiency virus. Here, we demonstrate that activation of NF-kappa B by RhoA does not exclusively promote its nuclear translocation and binding to the specific kappa B sequences. NF-kappa B is also involved in the regulation of the transcriptional activity of the c-fos serum response factor (SRF), since the activation of a SRE-dependent promoter by RhoA can be efficiently interfered by the double mutant Ikappa Balpha S32A/S36A, an inhibitor of the NF-kappa B activity. We also present evidence that RelA and p50 NF-kappa B subunits cooperate with the transcription factor C/EBPbeta in the transactivation of the 4 × SRE-CAT reporter. Furthermore, RhoA increases the levels of C/EBPbeta protein, facilitating the functional cooperation between NF-kappa B, C/EBPbeta , and SRF proteins. These results strengthen the pivotal importance of the Rho family of small GTPases in signal transduction pathways which modulate gene expression and reveal that NF-kappa B and C/EBPbeta transcription factors are accessory proteins for the RhoA-linked regulation of the activity of the SRF.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Gene expression is regulated by the interplay of different transcription factors which bind to specific DNA recognition motifs and cooperate with the basal machinery to initiate transcription. During the last few years, an emerging body of evidence is revealing the importance of crossed interactions between members of distinct families of transcription factors to form higher complexes, enabling the accurate regulation of this process. The serum response element (SRE)1 is a specific DNA sequence which is found in the promoter of several immediate-early genes (2). The prototypic c-fos SRE binds a ternary complex composed of a homodimer of p67SRF (serum response factor) and a third subunit, p62TCF (ternary complex factor), which belongs to the Ets family of accessory proteins. These TCF factors have the ability to bind a purine-rich motif 5' to the SRF-binding site, known as the Ets recognition domain, only when SRF is bound to DNA, and include Elk-1, SAP-1, and SAP-2/ERP/NET proteins. The formation of this SRE binding-ternary complex requires the conserved B-box motif of the Ets subunits and sequences located in the core domain of the SRF protein (coreSRF), which is a region that is also responsible of its DNA binding and dimerization capabilities (2-8).

The SRE has shown to be necessary and sufficient for the rapid induction of the c-fos proto-oncogen in response to different external stimuli such as serum, growth factors, and phorbol esters (2, 9). Furthermore, this DNA motif is a point of convergence of different signal transduction cascades activated by an extensive range of agonists. The regulation of the activity of the SRE is mediated by two different signaling pathways. The first mechanism is elicited by the multiple phosphorylation of TCFs within their C-terminal transactivation domain. Such phosphorylation can be triggered by distinct families of mitogen-activated protein kinases. Actually, whereas the classical Ras-Raf-MEK-ERK cascade is responsible of the phosphorylation of TCFs proteins after growth factors or phorbol esters stimulation (2, 10-14), JNK/SAPK and p38 have also been shown to phosphorylate TCFs in response to certain cytokines and environmental stress conditions (15-17).

The second signaling pathway which controls an efficient transcriptional activation through the SRE site is mediated by the SRF. Hill et al. (18) showed that this TCF-independent regulation is modulated by members of the Rho family of small GTPases, RhoA, Rac1, and Cdc42Hs. Indeed, stimulation of the transcriptional activity of the SRF induced by serum, lysophosphatidic acid (LPA), and AlF4- (an activator of heterotrimeric G proteins) is signaled by RhoA in NIH 3T3 cells, since the expression of the C3 component of the Clostridium botulinum toxin efficiently blocks this effect. Fromm et al. (19) have also found that the Galpha 12 subfamily of heterotrimeric G protein alpha  subunits is able to induce the SRE activity by a RhoA-dependent pathway. On the other hand, Rac1 GTPase plays an essential role in the activation of the c-fos SRE induced by certain agents such as the epidermal growth factor and hydrogen peroxide (20-21). Whereas Hill et al. (18) have described that Rac1 and Cdc42Hs GTPases can activate the SRF in a RhoA-independent manner, other authors have found a link between these signaling cascades (22).

The precise mechanism by which Rho proteins can modulate the transcriptional activation through the c-fos SRE is ill defined. It has been proposed that this regulation may be targeted by a second, unknown accessory protein, distinct from TCFs, which could interact with the DNA-bound p67SRF (3, 18, 23, 24). As other results suggest that the SRF contains different sequences which can inhibit its own transactivation capability (25), it is possible that such interaction could relieve the transactivation domain from this inhibitory effect. And, moreover, this putative recognition factor should be a critical target for Rho family-mediated signal transduction pathways.

Our group has recently demonstrated that the Rho family of small GTPases can efficiently induce the transcriptional activity of the nuclear factor-kappa B (NF-kappa B) (1, 26). The NF-kappa B complex is mainly composed of two subunits of 50 and 65 kDa which are retained in the cytoplasm by a third protein, Ikappa B. These Ikappa B inhibitory proteins block the ability of the dimer to translocate to the nucleus and activate gene expression (27-29). This transcription factor has shown to play a relevant role in the control of cell growth and apoptosis, along with different aspects of the immune and inflammatory responses (30-41). RhoA, Rac1, and Cdc42Hs are able to trigger the transactivation of the NF-kappa B dependent-HIV promoter in different cell lines. The mechanism involved is the conventional nuclear translocation of RelA/p50 and p50/p50 dimers, by a mechanism that involves the phosphorylation and proteolytic degradation of the inhibitory subunit Ikappa Balpha . Moreover, this activation is independent of that induced by H-Ras/Raf cascade (1, 26).

Different interactions of the NF-kappa B dimers with other families of transcription factors have been widely reported (reviewed in Ref. 27). It has been described that RelA can act as an accessory protein for the SRF and a physical association between both subunits have been demonstrated in vitro (42). The formation of this complex seems to be mediated through the Rel homology domain of RelA and the DNA-binding domain of SRF, which has shown to exert a negative effect on its transactivation ability. Furthermore, RelA functionally synergizes with SRF in the transactivation of a reporter construct dependent only on the SRE site, indicating that the direct or facilitated interaction between both proteins may neutralize the inhibitory functions of the core domain of SRF.

In the present study, we have investigated the implications of RhoA-dependent activation of NF-kappa B in the regulation of p67SRF function. We demonstrate that NF-kappa B modulates the transcriptional activity of the SRF induced by this GTPase. Furthermore, this mechanism may also involve a cross-talking of RelA and p50 NF-kappa B subunits with the transcription factor C/EBPbeta , which is also able to bind to the SRF and regulate its transactivation activity (43). Therefore, members of the NF-kappa B and C/EBP families of transcription factors can interact and behave as accessory proteins in the modulation of the transcriptional activity of the SRF induced by the small GTPase RhoA.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture and Transfections-- Simian COS-7 fibroblast-like cells were cultured in Dulbeccos's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 1 mM glutamine. Murine NIH 3T3 fibroblasts were grown in DMEM with 10% newborn calf serum. For transient expression assays, cells were transfected in 60-mm dishes by the calcium phosphate method as described (44). The amount of plasmidic DNA was kept constant at 9-10 µg/plate with the corresponding empty vector. The total amount of DNA was kept at 30 µg/100-mm plate with calf thymus DNA (Boehringer Mannheim). After the precipitate was removed, cells were incubated in DMEM, 0.5% fetal calf serum for the next 24 h. Cells were stimulated during the last 5 h of culture where indicated and harvested for the different assays. Transfection efficiency was normalized by co-transfection of the plasmid pCMV-beta -gal, and the beta -galactosidase assay as described previously (1).

Plasmids-- pCDNAIIIB plasmid (Invitrogen) and derived expression vectors encoding for constitutively activated RhoA (QL), Rac1 (QL), and Cdc42Hs (QL) proteins have been described previously (45). (-453/+80)HIV-LUC contains the NF-kappa B sites of the HIV enhancer/promoter and Delta NF-kappa B HIV-LUC contains a 3-base pair substitution in each of the NF-kappa B-binding sites (46, 47). The promoters of the different reporters contain the following specific motifs: 4 × SRE-CAT, (4X) (AGGATGTCCATATTAGGACATCT) the sequence of the SRE-binding site of the human c-fos gene 5' from a minimum promoter harboring the TATA box (54); SREMUT-CAT promoter contains the mutations (AGGATGTCAATACTAGGACATCT) that prevents binding of the SRF, as previously reported (1); SRE-beta -gal, the sequence of the SRE-binding site of the human c-fos gene 5' from a minimum promoter containing the TATA box; and 3D.A.CAT, a minimal c-fos promoter SRE with a TCF-defective binding site inserted 5' to a Xenopus gamma -actin TATA box (18). pMEX-RelA(p65) and pMEX-p50 were provided by Dr. Bravo. pMSV-C/EBPbeta was generously provided by Dr. Pérez-Castillo and contains the rat C/EBPbeta gene. pMSV-LIP was obtained by deletion of the 5' coding region of the C/EBPbeta gene, digested with the NcoI enzyme (48). The following plasmids have been previously described: pMEX derived vector encoding for a truncated Vav protein (PJC7) (49); PCEV27 derived vector encoding for a truncated Ost protein (50); and EXV-RasVal-12 (51) and pRcCMV-Ikappa Balpha S32A/S36A (52).

Gene Expression Analysis-- Analysis of the NF-kappa B activity was performed by transfection of the reporter containing the wild-type kappa B sites of the HIV enhancer/promoter, (-453/+80)HIV-LUC, and the one containing 3-base pair substitutions in each NF-kappa B site, Delta NF-kappa B HIV-LUC. Cells were harvested 24 h after transfection and the protein extracts were prepared by three consecutive cycles of freezing and thawing. The total amount of protein was determined with a commercial kit based on the Bradford method (Bio-Rad). 2 µg of protein were assayed for luciferase activity using a commercial kit (Promega). For the SRE-binding site, both 4 × SRE-CAT and 3D.A.CAT reporters were used in this study. Protein extracts were prepared and 10-50 µg were assayed for the chloramphenicol acetyltransferase (CAT) activity as described previously (53). Transfection efficiencies were corrected by the ratio of the luciferase or CAT activity and the beta -gal activity obtained in the same sample by co-transfection of the pCMV-beta -gal plasmid. None of the proteins used in this study affected considerably the levels of transcriptional activation of pCMV-beta -gal because similar levels were always observed when compared with the respective empty plasmids.

Measurement of the activation of the chromosomal SRE-beta -gal plasmid was performed as follows: NIH 3T3 cells were transfected with the pSV2Neo vector along with a SRE-beta -gal plasmid and selected for G418 resistance. Approximately 200 colonies obtained by serial dilution were tested for beta -galactosidase activity after serum stimulation. Four selected clones were then transfected with the pCDNAIIIB-derived expression vectors encoding for the constitutively activated Rho proteins and cells were incubated in DMEM, 0.5% fetal calf serum for the next 24 h. Cells were fixed in 1% glutaraldehyde and incubated at 37 °C for beta -gal activity staining, using 5-bromo-4-chloro-3-indoyl beta -D-galactoside as substrate. Efficiency of transfections were normalized by parallel transfections using the pCMV-beta -gal plasmid.

Western Blot Assays-- For protein expression assays, cells were transfected with the corresponding plasmids and incubated in DMEM, 0.5% fetal calf serum for the next 24 h. The lysis was performed in buffer containing 50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 0.5% Triton X-100, 0.5% sodium deoxycholate, 10 mM Na4P2O7, 50 mM sodium fluoride, 20 µg/ml leupeptin, 20 µg/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride. The total amount of protein was determined with a commercial kit based on the Bradford method (Bio-Rad). Lysates were obtained in 1 × SDS Laemmli buffer. Thirty micrograms of total protein were analyzed by SDS-electrophoresis on 10% polyacrylamide gels (SDS-PAGE). After transferring to nitrocellulose, the blots were incubated with the corresponding rabbit antiserum (p50, RelA(p65), C/EBPbeta ) (Santa Cruz Laboratories). Immunocomplexes were visualized by enhanced chemiluminescence detection (Amersham) using a biotinylated anti-rabbit antibody and streptavidin peroxidase.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Rho Proteins Activate Transcription through kappa B- and SRE-binding Sites in COS-7 Cells-- Rho proteins are able to activate the transcription factor NF-kappa B in diverse cell systems (1) and the serum response factor in NIH 3T3 fibroblasts (18). We aimed to investigate whether activation of NF-kappa B by Rho proteins was functionally related to the activation of the SRE-dependent transcriptional activity. We first identified a suitable cell system to carry out both assays, NF-kappa B activation and SRE-dependent transcription, under similar conditions. The NF-kappa B-dependent (-453/+80)HIV-luciferase (HIV-LUC) plasmid was used (47) as a reporter for NF-kappa B activity. This reporter contains two kappa B-binding sites within its enhancer region, which are mostly responsible for the transactivation of the HIV LTR. Fibroblast-like COS-7 cells were co-transfected with the cDNAs encoding for the constitutively activated forms of RhoA, Rac1, and Cdc42Hs (QL) proteins along with the HIV-LUC plasmid. As shown in Fig. 1A, an efficient transactivation of the HIV promoter could be readily observed. This effect was dependent on the kappa B-binding sites since the activation was completely avoided when a HIV-LUC reporter containing 3-base pair substitutions in each kappa B motif was used (data not shown). Under similar conditions, Rho proteins were also able to induce the transactivation of a 4 × SRE-CAT reporter in the same cell line (Fig. 1B). The 4 × SRE-CAT plasmid contains the CAT gene under the control of a minimum promoter composed of four copies of the sequence of the SRE of the human c-fos gene along with a TATA box (54). Similar results were obtained when both constitutively activated forms of two Rho family related exchange factors, Vav and Ost (55), were overexpressed (Fig. 1B). Although there is a clearly positive and reproducible response with a 3-4-fold induction by serum, this is reduced compared with other cell systems. We also were able to demonstrate a more than 10-fold activation by serum when the NIH 3T3 cell system was used instead of the COS-7 cell sytem using the same reporter vectors (data not shown). These results demonstrate that these three members of the Rho family of GTPases mediate in the signal transduction pathways implicated in the activation of the transcription factor NF-kappa B and in the up-regulation of intracellular cascades which promote gene expression through the SRE-binding site in the simian fibroblast-like COS-7 cells.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 1.   Rho proteins activate transcription through the kappa B and the SRE binding motifs in COS-7 cells. A, Rho proteins induce the transcriptional activation of the HIV-LUC reporter. COS-7 cells were co-transfected with 0.5 µg of (-453/+80)HIV-LUC and 1 µg of pCMV-beta -gal per 60-mm plate along with 3 µg of the plasmid pCDNAIIIB or the derived vectors expressing RhoA QL, Rac1 QL, or Cdc42Hs QL. Cells transfected with pCDNAIIIB were stimulated with TNFalpha (10 ng/ml) (vector + TNFalpha ) 5 h before harvesting. Luciferase activity was determined 24 h after transfection. Data represent the mean of a single experiment performed in triplicate ± S.D. Results are expressed as fold induction considering as 1 the luciferase activity of the cells transfected with the empty vector. Same results were observed in three independent experiments. B, Rho proteins induce the transcriptional activation of the 4 × SRE-CAT reporter. COS-7 cells were co-transfected with 3 µg of 4 × SRE-CAT and 1 µg of pCMV-beta -gal per 60-mm plate along with 3 µg of pCDNAIIIB or the derived vectors expressing RhoA QL, Rac1 QL, or Cdc42Hs QL, pMEX or pMEX-vav, pCEV27, or pCEV27-ost. Cells transfected with pCDNAIIIB were stimulated with 20% fetal bovine serum (vector + 20% FBS) 5 h before harvesting. CAT activity was determined 24 h after transfection. Data represent the mean of a single experiment performed in triplicate ± S.D. Results are expressed as fold induction considering as 1 the CAT activity of the cells transfected with the empty vector. Same results were observed in three independent experiments. C, Rho proteins induce the beta -galactosidase activity of SRE-beta -gal stable transfectants. SRE-beta -gal derived NIH 3T3 cells were transfected with 3 µg of the plasmid pCDNAIIIB or the derived vectors expressing RhoA QL, Rac1 QL, or Cdc42Hs QL and starved from serum for 48 h. Cells transfected with pCDNAIIIB were stimulated with 20% fetal bovine serum (vector + 20% FBS) 5 h before harvesting. beta -Galactosidase activity was determined 48 h after transfection. Data represent the mean of a single experiment performed in triplicate ± S.D. Results are expressed as fold induction considering as 1 the beta -galactosidase activity of the cells transfected with the corresponding empty vector. Similar data were observed in other three SRE-beta -gal derived clones. Three independent experiments were performed for each derived clone with similar results.

Artificious regulation of the SRE-driven transcription due to the characteristic episomal replication of a transfection system based on COS-7 cells could affect the results. In order to eliminate this possibility we also investigated whether SRE-dependent transcription could be stimulated by Rho proteins in cells stably transfected with a plasmid carrying the SRE-binding site in a non-episomal vector. NIH 3T3 cells were stably transfected with the pSV2Neo vector along with the SRE-beta -gal plasmid and selected for G418 resistance. Over 200 different resistant colonies obtained by serial dilution were isolated and tested for beta -galactosidase activity after serum stimulation. Four of them that scored close to 100% staining when stimulated by serum were selected for further analysis. Cells were transiently transfected with the pCDNAIIIB-derived expression vectors encoding for the constitutively activated forms of RhoA, Rac1, and Cdc42Hs GTPases and cells expressing the beta -galactosidase were scored as positive. Efficiency of transfection for each plasmid preparation was normalized by parallel transfections using the beta -galactosidase gene placed under control of the CMV promoter, allowing for constitutive expression of the beta -galactosidase enzyme. As shown in Fig. 1C, the three GTPases were able to promote transactivation through the chromosomal SRE site in one of the selected clones by at least 2-fold. Cdc42Hs was much more efficient, suggesting additional signaling pathways activated by Cdc42 to those activated by RhoA and Rac1, in agreement with the results reported by Alberts et al. (56). Similar results were observed when the other three independent clones were used (data not shown). Thus, these results provide a strong support to the implication of Rho GTPases in signal transduction pathways which determine the activation of transcription due to the SRE sequences under physiological conditions and establishes that the COS-7 cell system is appropriate to carry out the proposed experiments.

NF-kappa B Activity Is Required for Transcriptional Activation of the SRE by RhoA-- It has been previously reported that the different Rel/NF-kappa B proteins are able to interact physically and functionally with members of other families of transcription factors such as AP1, Sp1, Stat6, ATF, HMG/Y, the glucocorticoid receptor, TBP, TFIIB, and C/EBP (57-66). Cross-talkling between subunits of different families of transcription factors seems to be a relevant general event in the regulation of gene expression. In particular, previous studies suggested that NF-kappa B might also participate in the regulation of the transcriptional activity of the serum response factor (p67SRF), and a physical interaction between RelA and this protein had been observed in vitro (42, 67, 68). Thus, we explored whether the activation of NF-kappa B by Rho proteins could play any role in the cascades controlling transcription through the SRE-binding site.

For that purpose, an inhibitor of the NF-kappa B activity, the double mutant Ikappa Balpha S32A/S36A was used. Ikappa Balpha is a member of the Ikappa B family, having the ability to retain the NF-kappa B complexes in the cytoplasm in their inactive state. The mutation in the residues Ser32 and Ser36 avoids the inducible proteolytic degradation of the protein in response to external stimuli (52, 69-73). As previously reported, activation of NF-kappa B by RhoA, Rac1, and Cdc42Hs GTPases is efficiently blocked by the overexpression of Ikappa Balpha S32A/S36A (1). Simian COS-7 cells were co-transfected with the 4 × SRE-CAT reporter and the expression vector corresponding to the constitutively activated RhoA along with increasing doses of the cDNA of the double mutant Ikappa Balpha S32A/S36A. As shown in Fig. 2A, inhibition of the NF-kappa B activity efficiently interfered in the transactivation of the SRE-dependent promoter induced by RhoA, in a dose-dependent manner. A similar assay coexpressing the activated version of each GTPase (RhoA QL, Rac1 QL, or Cdc42Hs QL) along with the Ikappa Balpha S32A/S36A protein was then performed. While the transactivation of the SRE-dependent promoter induced by RhoA could be inhibited by Ikappa Balpha S32A/S36A, it had no effect on the activation of the SRE due to Rac1 or Cdc42Hs overexpression (Fig. 2B). However, activation of the 4 × SRE-CAT reporter by serum was not affected by the overexpression of the Ikappa Balpha S32A/S36A mutant, an indication of a rather specific effect. Thus, the requirement of the NF-kappa B activity for the SRE transcriptional activation can be by-passed by alternative signaling pathways also promoted by Rac1 and Cdc42Hs.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 2.   RhoA-induced transcriptional activation through the SRE site depends on NF-kappa B activity. A, dose-dependent inhibition of the RhoA-induced transcriptional activation of the 4 × SRE-CAT reporter by Ikappa Balpha S32A/S36A. COS-7 cells were co-transfected with 3 µg of 4 × SRE-CAT and 1 µg of pCMV-beta -gal per 60-mm plate along with 3 µg of pCDNAIIIB or the derived vector expressing RhoA QL and 0, 0.1, 0.4, or 2 µg of pRcCMV-Ikappa Balpha S32A/S36A. CAT activity was determined 24 h after transfection. Data represent the mean of a single experiment performed in triplicate ± S.D. Results are expressed as percentage of maximal induction related to the stimulation obtained with each plasmid alone. Similar results were observed in three independent experiments. B, the mutant Ikappa Balpha S32A/S36A inhibits the transcriptional activation of the 4 × SRE-CAT reporter induced by RhoA, but not Rac1 or Cdc42Hs. COS-7 cells were co-transfected with 3 µg of 4 × SRE-CAT and 1 µg of pCMV-beta -gal per 60-mm plate along with 3 µg of pCDNAIIIB or the derived vectors expressing RhoA QL, Rac1 QL, or Cdc42Hs QL and 2 µg of pRcCMV or pRcCMV-Ikappa Balpha S32A/S36A. Cells transfected with pCDNAIIIB were stimulated with 20% fetal bovine serum (vector + 20% FBS) 5 h before harvesting. CAT activity was determined 24 h after. Data represent the mean of a single experiment performed in triplicate ± S.D. Results are expressed as percentage of maximal induction related to the stimulation obtained with each plasmid alone. Similar results were observed in three independent experiments. C, the mutant Ikappa Balpha S32A/S36A inhibits the transcriptional activation of the 4 × SRE-CAT reporter induced by RhoA-related exchange factors. COS-7 cells were co-transfected with 3 µg of 4 × SRE-CAT and 1 µg of pCMV-beta -gal per 60-mm plate along with 3 µg of pCDNAIIIB, pCDNAIIIB-rhoA QL, pMEX, pMEX-vav, pCEV27, or pCEV27-ost and 2 µg of RcCMV or pRcCMV-Ikappa Balpha S32A/S36A. CAT activity was determined 24 h after transfection. Data represent the mean of a single experiment performed in triplicate ± S.D. Results are expressed as percentage of maximal induction related to the stimulation obtained with each plasmid alone. Similar results were observed in three independent experiments.

We also explored whether the activation of the 4 × SRE-CAT reporter by specific Rho-related exchange factors was affected by the expression of Ikappa Balpha S32A/S36A. Ost and Vav proteins are two members of the Dbl family of specific exchange factors for the Rho family of small GTPases. In addition to the in vitro guanine nucleotide exchange activity exhibited by these proteins, several in vivo approaches have allowed to adscribe to these molecules certain specificity for the different Rho GTPases (reviewed in Ref. 74). In our assays, the Vav oncogene is able to activate the transcription factor NF-kappa B in a signaling pathway which involves Rac1 GTPase, but not RhoA or Cdc42Hs. On the contrary, activation of the HIV-LUC reporter due to Ost overexpression is efficiently inhibited by RhoA-Asn19 and Cdc42Hs-Asn17 dominant negative mutants, showing that RhoA and Cdc42, but not Rac1, mediate in the activation of NF-kappa B induced by the Ost exchange factor (26).

Next, COS-7 cells were co-transfected with the corresponding cDNAs of the constitutively activated Vav or Ost genes, along with the pRcCMV-Ikappa Balpha S32A/S36A plasmid and the 4 × SRE-CAT reporter. In agreement with the results described above, activation of the SRE due to Vav overexpression was not significatively inhibited by the expression of the Ikappa Balpha S32A/S36A protein, showing that Rac1 activates transcription through the SRE-binding site by additional pathways (Fig. 2C). However, this inhibitor was able to block the SRE-dependent transcription induced by the Ost oncogene, suggesting the activation of complementary signals that make Ost dependent on RhoA but not Cdc42 for the activation of SRF. From these experiments, we can conclude that activation of the SRE-binding site by RhoA critically involves a NF-kappa B-dependent cascade.

Expression of the Ikappa Balpha S32A/S36A Mutant Blocks the Activation of SRE-dependent Transcription by Lysophosphatidic Acid-- It has been described that activation of the SRE elicited by several extracellular agonists may be signaled by different Rho GTPases. Indeed, expression of the C3 component of the C. botulinum toxin is able to inhibit the transcriptional activity of the SRF induced by serum, LPA, and AlF4- (an activator of heterotrimeric G proteins), indicating that these stimuli activate SRF by RhoA-dependent pathways (18). It is also reported that this GTPase is involved in the endothelin-1-induced nuclear signaling to the c-fos SRE (75). On the other hand, the dominant negative mutant Rac1-Asn17 blocks the activation through this binding site in response to EGF and hydrogen peroxide (20, 21).

Since transactivation of the 4 × SRE-CAT induced by RhoA seemed to be dependent on the NF-kappa B activity (Fig. 2A), we investigated whether the expression of the Ikappa Balpha S32A/S36A mutant had any effect in the activation of the SRE by LPA, a physiological activator of the RhoA signaling cascade. To that end, COS-7 cells were co-transfected with the pRcCMV or pRcCMV-Ikappa Balpha S32A/S36A plasmid along with the (-453/+80)HIV-LUC or the 4 × SRE-CAT reporter. After removal of the precipitate, cells were treated with LPA for 5 h and total extracts were assayed for luciferase activity (NF-kappa B assay) or CAT activity (SRE assay). We observed that this physiological stimulus was able to efficiently induce the transactivation of both promoters in these cells (Fig. 3). Overexpression of the Ikappa Balpha S32A/S36A mutant inhibited the transactivation of both NF-kappa B- and SRE-dependent reporters by LPA. These results indicate that activation of NF-kappa B is a relevant event in the physiological regulation of the SRE transcriptional activity induced by a RhoA-dependent extracellular stimulus.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   LPA-induced transcriptional activation through the kappa B and SRE-binding sites is inhibited by the Ikappa Balpha S32A/S36A mutant. COS-7 cells were co-transfected with 1 µg of pCMV-beta -gal and 2 µg of pRcCMV or pRcCMV-Ikappa Balpha S32A/S36A along with either 0.5 µg of (-453/+80)HIV-LUC or 3 µg of 4 × SRE-CAT, per 60-mm plate. Cells were stimulated with (10 or 30 µM) LPA 5 h before harvesting. Luciferase and CAT activities were determined 24 h after transfection. Data represent the mean of a single experiment performed in triplicate ± S.D. Results are expressed as fold induction considering as 1 the activity of the cells transfected with the empty vector. Same results were observed in three independent experiments.

RelA and p50 Subunits Cooperate with RhoA in the Transactivation through the SRE-binding Site-- The mechanism by which NF-kappa B affected the transactivation through the SRE was then investigated. We had previously described that both RelA/p50 and p50/p50 dimers translocate to the nucleus due to RhoA overexpression (1). Thus, we explored whether these subunits could cooperate with RhoA in the activation of the SRE-dependent reporter. To that end, we used the corresponding expression vectors of the RelA and p50 transcription factors. Overexpression of both proteins was achieved by transient transfection of the corresponding plasmids into COS-7 cells (Fig. 4A). Both subunits were able to potentiate the transactivation of the HIV-LUC reporter induced by RhoA (Fig. 4B).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Cooperation between NF-kappa B and RhoA in the SRE-dependent transcriptional activation. A, overexpression of p50 and RelA NF-kappa B subunits. COS-7 cells were transiently transfected with 1 µg of pMEX, pMEX-p50, or pMEX-RelA per 60-mm plate. Total lysates were subjected to Western blot analysis after SDS-PAGE and immunoblotted with the corresponding antiserum (anti-p50 or anti-RelA; Santa Cruz Laboratories). B, p50 and RelA cooperate with RhoA in the transactivation of the HIV-LUC reporter. COS-7 cells were co-transfected with 0.5 µg of (-453/+80)HIV-LUC and 1 µg of pCMV-beta -gal, 1 µg of pCDNAIIIB or pCDNAIIIB-rhoA QL, along with 0.1 or 0.5 µg of pMEX, pMEX-RelA, or pMEX-p50 per 60-mm plate. Luciferase activity was determined 24 h after transfection. Data represent the mean of a single experiment performed in triplicate ± S.D. Results are expressed as fold induction over the luciferase activity obtained with the corresponding empty vector. Similar results were observed in two independent experiments. C and D, RelA and p50 cooperate with RhoA in the transactivation of the 4 × SRE-CAT reporter. COS-7 cells were co-transfected with 3 µg of 4 × SRE-CAT, 1 µg of pCMV-beta -gal, 1 µg of pCDNAIIIB or pCDNAIIIB-rhoA QL, along with 0.1 or 0.5 µg of pMEX, pMEX-RelA (C), or pMEX-p50 (D) per 60-mm plate. CAT activity was determined 24 h after transfection. Data represent the mean of a single experiment performed in triplicate ± S.D. Results are expressed as fold induction over the CAT activity obtained with the corresponding empty vector. Same results were observed in three independent experiments.

COS-7 cells were co-transfected with a suboptimal dose of the expression vector corresponding to RhoA QL and increasing concentrations of the cDNA of the RelA or p50 protein, along with the 4 × SRE-CAT plasmid. Expression of the RelA subunit along with the constitutively activated RhoA GTPase cooperated in the transactivation of the SRE-dependent reporter (Fig. 4C). Franzoso et al. (42) have previously shown that RelA but not p50 synergizes with SRF in the transactivation of the interleukin 2R-alpha promoter. By contrast, both RelA and p50 potentiated the activation of the 4 × SRE-CAT reporter by RhoA (Fig. 4D). As control, a similar experiment was performed using the 3.DA.CAT plasmid, which contains the CAT gene under the regulation of a minimal promoter with the c-fos-derived SRF-binding site but defective for TCF binding (18). The same effect was observed regarding the cooperation between RhoA and both RelA and p50 proteins, verifying that the NF-kappa B-dependent activation of the SRE is mediated by the SRF-linked pathway (data not shown). Finally, this effect was specific for the SRE site, since no competition was observed when a similar construct carrying the NF-kappa B site was used (Ref. 1, and data not shown). All these results corroborate that RhoA and NF-kappa B complexes are placed in the same signal transduction cascade to activate the SRE-binding site.

NF-kappa B-dependent Activation of the SRE-binding Site by RhoA Involves the C/EBP Family of Transcription Factors-- Binding of C/EBPbeta dimers to the c-fos SRE within a region overlapping and immediately 3' to its CArG box has been shown to be required for maximal contribution to c-fos activation (43, 76, 77). C/EBPbeta is included in the C/EBP family of transcription factors, characterized by the presence of a basic region involved in DNA binding and a leucine zipper motif which allows protein dimerization (bZIP motif) (78, 79). C/EBPalpha , C/EBPbeta , C/EBPgamma , C/EBPdelta , C/EBPepsilon , and CHOP-10 have been identified as members of this family, binding to specific DNA sequences as distinct homo- or heterodimers. Different members of the C/EBP and NF-kappa B families of transcription factors are able to synergize efficiently in the transcriptional regulation of certain promoters and, particularly, physical interactions between C/EBPbeta and RelA or p50 have been described (57, 68, 80-84). All these data and the results reported by Stein et al. (59) that suggested an increase of gene expression mediated by c-fos SRE in the presence of C/EBP and NF-kappa B transcription factors, prompted us to further investigate whether such cooperation was involved in the mechanism induced by RhoA regarding SRE activation.

Transcriptional activity assays were carried out co-transfecting the expression vector encoding for the constitutively activated form of RhoA along with the cDNAs of the RelA and the C/EBPbeta proteins and the 4 × SRE-CAT reporter, which contains in its core the C/EBP-binding site (Fig. 5A). A cooperative effect in the promoter transactivation was observed when the RhoA GTPase was coexpressed with C/EBPbeta alone. Moreover, the combined expression of RhoA, RelA, and C/EBPbeta proteins potentiated further the transcriptional activation through the SRE-binding site. By contrast, the same promoter carrying a mutated SRE site but an intact C/EBPbeta site was not functional after expression of the RelA or C/EBPbeta proteins (Fig. 5B), an indication that both RelA and C/EBPbeta were unable to stimulate transcription by themselves and require a functional SRE site. Similar results were obtained when RhoA and C/EBPbeta were coexpressed along with the p50 subunit (Fig. 5C and data not shown). Thus, activation of RhoA triggers the translocation of NF-kappa B dimers to the nucleus, promoting their binding to the kappa B-specific sequences and also enabling the cooperation with the C/EBPbeta protein in the transcriptional regulation of the SRE site in an SRF-dependent manner. Therefore, cross-talking between NF-kappa B and C/EBPbeta transcription factors is an intracellular event regulated by a RhoA-dependent signal transduction pathway. These results also suggest that NF-kappa B and C/EBPbeta can act as accessory factors for SRE-dependent transcription, which could liberate the SRF from its own inhibited transcriptional capability. On the contrary, a cooperation among H-Ras, NF-kappa B, and C/EBPbeta was not observed (data not shown). Thus, the latter transcription factors may play a role in conjunction with the SRF in the TCF-independent pathway for the transcriptional activation through the SRE.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   C/EBPbeta and NF-kappa B cooperate for RhoA-induced transcriptional activation through the SRE motif in an SRF-dependent manner. COS-7 cells were co-transfected with 3 µg of 4 × SRE-CAT (A and C) or a mutated SRE site as described under "Experimental Procedures," SREMUT-CAT (B) along with 1 µg of pCMV-beta -gal, 1 µg of pCDNAIIIB or pCDNAIIIB-rhoA QL along with 0.5 µg of pMSV or pMSV-C/EBPbeta , and 0.1 µg of pMEX or pMEX-RelA (A) or pMEX-p50 (B), per 60-mm plate. CAT activity was determined 24 h after transfection. Data represent the mean of a single experiment performed in triplicate ± S.D. Results are expressed as fold induction over the CAT activity obtained with the corresponding empty vector. Similar results were observed in two (B) or three independent experiments (A and C).

Inhibition of the RhoA-dependent Activation of the SRE-binding Site by a Specific Inhibitor of the C/EBP Family of Transcription Factors-- The C/EBPbeta gene encodes for three in-frame methionines which can potentially give rise to three translation products of 38, 35, and 20 kDa (rat or murine genes). p38 and p35 (LAP) are active proteins, while p20C/EBPbeta (also known as LIP) behaves as a competitive inhibitor of transcription because it lacks the N-terminal transactivation domain (48). Sealy et al. (43) have reported that both p35 and p20 homodimers as well as p35/p20 heterodimers contribute to the SRE complex at the c-fos promoter in NIH 3T3 cells, while overexpression of p20C/EBPbeta (LIP) is able to inhibit its activation by serum stimulation. In order to corroborate that C/EBPbeta was implicated in the regulation of SRF by RhoA, we used LIP as a specific repressor of the activity of this transcription factor.

COS-7 cells were co-transfected with the 4 × SRE-CAT reporter and the expression vector corresponding to the constitutively activated RhoA, along with the cDNA for LIP (Fig. 6A). Expression of such a specific inhibitor was able to block the transactivation of the SRE-dependent promoter due to either LPA stimulation or RhoA overexpression. Furthermore, the RhoA-dependent activation of the SRE binding motif inhibited by LIP was fully restored by co-transfection of the full-length active C/EBPbeta . These results suggest that RhoA regulates the SRE through a signaling cascade which also involves the transcription factor C/EBPbeta .


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 6.   C/EBPbeta is involved in the transcriptional activation through the SRE motif regulated by RhoA. A, LIP repressor inhibits the transactivation of the 4 × SRE-CAT reporter induced by RhoA. COS-7 cells were co-transfected with 3 µg of 4 × SRE-CAT and 1 µg of pCMV-beta -gal, 1 µg of pCDNAIIIB or pCDNAIIIB-rhoA QL along with 0.3 µg of pMSV-LIP and 0.5 µg of pMSV-C/EBPbeta per 60-mm plate. Cells were stimulated with 30 µM LPA (vector + LPA) 5 h before harvesting. CAT activity was determined 24 h after transfection. Data represent the mean of a single experiment performed in triplicate ± S.D. Results are expressed as percentage of maximal induction related to the stimulation obtained with each plasmid alone. Same results were observed in three independent experiments. B, RhoA induces the expression of C/EBPbeta . NIH 3T3 cells were transfected with 5 µg of pCDNAIIIB or pCDNAIIIB-rhoA QL per 60-mm plate. Cells tranfected with the control vector were stimulated for 1, 3, and 5 h with 10 µM forskolin (FK) (Sigma). Total lysates were subjected to Western blot analysis after SDS-PAGE and immunoblotted with a C/EBPbeta -specific antiserum (Santa Cruz Laboratories).

RhoA Affects the Levels of the C/EBPbeta Protein-- The above results indicate that RhoA is able to modulate the SRE-dependent transcription by a mechanism that depends upon the function of C/EBPbeta . The activity of C/EBPbeta is controlled at the transcriptional level, by direct activation of its expression (85-87) or by post-translational modifications (76, 88-90). When RhoA (QL) was transiently overexpressed in NIH 3T3 fibroblasts, an increase of the level of the C/EBPbeta protein was observed (Fig. 6B). Under similar conditions, treatment with forskolin, an activator of PKA, also induced a time-dependent increase in the levels of the C/EBPbeta protein, as described previously (87). Although we cannot exclude the possibility that RhoA could also affect C/EBPbeta function by other mechanisms such as post-translational modifications, these results strongly support the evidence, provided in this study, of the regulation of the SRE through the participation of NF-kappa B, C/EBPbeta , and SRF proteins.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Rho proteins regulate critical biological processes such as cell growth, transformation and metastasis, apoptosis, response to stress, and certain aspects of development (44, 45, 74, 91-103). Recently, our group has demonstrated that the human proteins RhoA, Rac1, and Cdc42Hs (three prototype members of the Rho family) activate NF-kappa B in diverse cell types (1) by at least two alternative pathways (26). Hill et al. (18) have recently demonstrated that in NIH 3T3 cells, the serum response factor (p67SRF) is regulated by Rho-dependent signaling pathways. This activation is achieved by mechanisms independent of the signal transduction cascades related to TCFs. Although it is not clear how Rho proteins modulate the transcriptional activation of the SRE, it has been suggested that this mechanism is dependent on a second accessory protein targeted by the Rho family of GTPases. Such a molecule could associate with the DNA-bound SRF and relieve the transactivation domain of the SRF from its own inhibitory regulation (3, 18, 23-25). In this study, we have explored this signaling pathway and found that the transcriptional activation through the SRE induced by RhoA, but not Rac1 or Cdc42Hs, is dependent on the activity of the transcription factor NF-kappa B.

Three prototype members of the Rho family, RhoA, Rac1, and Cdc42Hs, induce the transcriptional activation of both NF-kappa B and a SRE-dependent promoter in the simian COS-7 system. NIH 3T3-derived clones stably transfected by a SRE-beta -gal plasmid were used to demonstrate that RhoA, Rac1, and Cdc42Hs induce the transcriptional activation through a chromosomal SRE motif. Alberts et al. (56) have recently reported that RhoA, Rac1, and Cdc42 regulate transcriptional activation by SRF (18). At least RhoA and Cdc42 requires also H4 hyperacetylation as an additional signal for the activation of SRF-regulated chromosomal templates. Furthermore, while RhoA does not provide by itself the cooperating signals required for the induction of H4 hyperacetylation, Cdc42 does. The partial discrepancies in the results of Alberts et al. (56) and ours may be due to differences in the sensitivity of the methodologies used, microinjection versus transient transfections. However, both reports are consistent with the fact that Cdc42 is more efficient than RhoA for the activation of SRF-regulated chromosomal templates, although the basis for this difference is currently unknown.

Previous reports showed that NF-kappa B could modulate the activity of p67SRF (42, 67). We investigated whether the activation of the SRF by Rho GTPases could involve a NF-kappa B-dependent cascade. Our results clearly demonstrate that the double mutant Ikappa Balpha S32A/S36A was able to block the activation of the 4 × SRE-CAT reporter induced by RhoA. At the same time, activation of the 4 × SRE-CAT induced by the stimulation of COS-7 with LPA was also blocked by the ectopic expression of the Ikappa Balpha S32A/S36A mutant. All these results demonstrate that NF-kappa B is critically involved in the signaling cascade triggered by RhoA to regulate SRE-dependent transcription. The cooperative effect observed when RhoA is co-expressed with the NF-kappa B subunits RelA or p50 also agrees with this hypothesis. Similar results were obtained with the 3D.A.CAT reporter which is lead by an SRE site defective for TCF binding, suggesting that NF-kappa B is involved in the regulation of the SRE by SRF. Indeed, Franzoso et al. (42) have found that RelA is able to physically interact in vitro with the DNA-binding region of SRF (coreSRF), through its Rel homology domain. Thus, NF-kappa B subunits could act as accessory proteins for the SRF, in order to regulate the activity of the SRE, liberating the negative effect exerted by the DNA-binding and dimerization domains, as other authors have previously suggested (18, 25, 42).

From the experiments shown here we cannot conclude whether RelA and p50 can bind to p67SRF as prototypical NF-kappa B dimers or as monomers, although NF-kappa B is supposed to bind to other transcription factors in its dimeric configuration (59). It has been described that p50 and SRF are not able to interact physically and that they do not cooperate functionally in SRE-driven transcription (42). In contrast, we have observed similar results by coexpression of RhoA along with the RelA or p50 subunits. RhoA promotes the translocation of both RelA/p50 and p50/p50 dimers to the nucleus (1). Thus, it can be proposed that RelA/p50 may be the NF-kappa B dimer involved in the regulation of SRF and that the physical interaction with such a factor could be mediated by the RelA subunit.

The region between residues 204 and 234 of RelA is involved in its interaction with SRF, while the dimerization between RelA and p50 is mediated by residues 222 to 231, all of them located in the Rel homology domain (42, 104). Thus, interaction of RelA with the SRF is feasible through residues 204 to 222. Furthermore, the positive effect observed on SRE-dependent transcription when p50 is overexpressed along with RhoA could be explained if the excess p50 subunit induced its dimerization with RelA and translocation to the nucleus, where it would contribute to the activation of the SRF. On the other hand, the region of p67SRF implicated in complexing with RelA overlaps the previously described domain which is responsible for neutralization of its own transcriptional activity, favoring the hypothesis that NF-kappa B acts as an accessory protein for SRF by affecting its functions.

Nevertheless, the Ikappa Balpha S32A/S36A mutant was not able to block the activation of the 4 × SRE-CAT by Rac1 or Cdc42Hs or Vav, an exchange factor specific for Rac1 in vivo (26), suggesting that the requirement for the NF-kappa B activity can be by-passed by alternative mechanisms. This effect can be explained by the fact that both Rac1 and Cdc42Hs may regulate the activity of the SRE through the TCF-dependent pathway, since they activate JNK/SAPK and p38 cascades (1, 45, 97), and such kinases have been found to phosphorylate TCFs (15-17). The effects reported here were specific for the SRE site, since no competition was observed using an NF-kappa B site and was abolished by a mutated SRE construct.

We demonstrate that activation of the SRE by RhoA involves another factor, the C/EBPbeta , which belongs to the family of CCAAT box enhancer-binding proteins, characterized by the presence of the bZIP motif (78-79). These results are in agreement with others previously described that suggest an increase of gene expression mediated by c-fos SRE in the presence of C/EBP and NF-kappa B transcription factors (59). These authors had observed a strong synergistic stimulation of a SRE-dependent reporter due to the joint overexpression of RelA(p65) NF-kappa B and C/EBPbeta . Different C/EBP and NF-kappa B subunits are able to synergize for the transcriptional regulation of certain promoters and, particularly, physical interactions between C/EBPbeta and RelA or p50, through their bZIP and Rel homology domains, respectively, have been described (57, 59, 68, 80-84, 105). It has been suggested that, at least, an additional factor could contribute to the C/EBP dimer bound neighboring to the SRE. Sealy et al. (43) have reported that approximately 50% of the C/EBP complex which is bound to 32P-labeled SRE DNA remains unaffected when competed by C/EBPbeta antibodies, although they were not able to visualize any supershift when a RelA(p65)-specific antibody was used. In keeping with this, two proteins of 64 and 43 kDa have been described to associate with rNFIL-6 (C/EBPbeta ) by immunoprecipitation with a specific antibody, in cells stimulated with forskolin (76).

The p20/C/EBPbeta (LIP) protein acts as a transdominant negative regulator of the C/EBP activity (48). It is known that the regulation of gene transcription by C/EBPbeta involves a precise balance of both activator and inhibitor forms (43, 48, 106). When p20/C/EBPbeta (LIP) was transfected along with RhoA, the activation of the SRE was efficiently inhibited. Moreover, the full activity was recovered by overexpression of the full-length C/EBPbeta , a demonstration of the specificity of the inhibitory effect by LIP. All these results support the idea of cooperation between NF-kappa B and C/EBPbeta subunits in order to potentiate the transcriptional activation through the SRE, as shown schematically in Fig. 7. This cooperation is dependent on SRF binding to the SRE site since it was lost when a mutated SRE site was used and was not observed by expressing NF-kappa B or c/EBPbeta alone or in combination, in the absence of RhoA.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 7.   Model for the activation of SRF-dependent transfection by RhoA. Activation of the SRF-dependent transcription by RhoA is mediated by NF-kappa B subunits p50 and RelA/p65 as well as C/EBPbeta . Activation of NF-kappa B by RhoA follows the conventional nuclear translocation of RelA/p50 and p50/p50 dimers by phosphorylation and proteolytic degradation of the inhibitory subunit Ikappa Balpha (1, 26). Activation of C/EBPbeta is achieved at least by transcriptional up-regulation of the factor by an as yet unknown effector.

We have also observed an increase in the level of the C/EBPbeta protein induced by RhoA in NIH 3T3. Such an increase could be originated by the transcriptional activation of the C/EBPbeta gene or the stabilization of its mRNA. From our experiments, we cannot conclude which of these mechanisms is regulated by RhoA. Regarding the transcription of the C/EBPbeta gene, it is mostly controlled by two CREB sites situated close to the TATA box (87). The CREB protein is functionally regulated by phosphorylation, which can be mediated by PKA- or p38-linked signaling cascades. RhoA is not capable of activating the p38 pathway in NIH 3T3 and it is also reported that LPA, a physiological activator of RhoA signaling, induces a decrease in cAMP levels (97, 107). Thus, if RhoA increases the level of C/EBPbeta by activating transcription of the gene, this could be triggered by the regulation of CREB by a not yet defined pathway or through other specific DNA sequences located in the promoter. Such hypothesis deserves further investigation. Finally, the c-Jun NH2-terminal kinase (JNK) pathway is involved in the stabilization of interleukin-2 mRNA (108). Thus, it would also be interesting to study whether RhoA could be implicated in a similar process regarding the stabilization of the C/EBPbeta mRNA.

Mitogen stimulation induces cell division, triggering the transcription of a wide range of immediate early genes, which relies most on post-translational modification of pre-existing transcription factors. As an example of such proteins, the NF-kappa B dimers remain in the cytoplasm in an inactive state and may elicit a rapid and efficient transcriptional response after stimulation by different agonists. Activation of NF-kappa B is an immediate early event after serum stimulation of quiescent fibroblasts, suggesting that its activity is important for G0-G1 transition (30). Therefore, NF-kappa B dimers may also regulate the transcriptional activity of other factors activated in response to serum, promoting a synergistic effect as we have observed with the ternary complex which bind to the c-fos SRE.

Cross-talking between subunits of different families of transcription factors was shown to be a critical event in the regulation of gene transcription, and actually NF-kappa B subunits can interact with different members of other families of transcription factors. Regarding the complexes involving the SRF, we cannot exclude that other proteins could interact with NF-kappa B and/or SRF, leading to the formation of higher transcription complexes, since other transcription coactivators have already been shown to interact with NF-kappa B (109-112). Thus, the picture of the mechanism by which Rho proteins regulate SRE-dependent transcription may still not be complete. In fact, what has been demonstrated in this study for the interaction of SRF, RelA, p50, and C/EBPbeta cannot be fully applied to Rac1 and Cdc42Hs, two important prototype members of the same family of Rho GTPases. Thus, each member of the Rho family of GTPases seems to serve specific signaling wirings that although controlling similar targets may exert different biological responses.

    ACKNOWLEDGEMENTS

We thank M. Karin for the HIV-LUC plasmids; S. Gutkind for the pCDNAIII vectors carrying the rho genes; A. Israël for the Ikappa Balpha S32A/S36A mutant; R. Treisman for the 3D.A.CAT reporter; R. Bravo for pMEX-RelA(p65) and pMEX-p50 plasmids; A. Pérez-Castillo for the pMSV-C/EBPbeta expression vector. We also thank X. Bustelo and T. Miki for pMEX-vav and PCEV27-ost plasmids.

    FOOTNOTES

* This work was supported by Spanish Department of Health Grants FIS-96/2136 and FIS-98/0514 and Comunidad de Madrid Grants 07-114-96 and 08.1/0024/97.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Contributed equally to the results of this work.

§ Fellow from Comunidad de Madrid (CAM).

Fellow from Fundación Ramón Areces.

parallel To whom correspondence should be addressed: Instituto de Investigaciones Biomédicas, Arturo Duperier, 4 28029 Madrid, Spain. Tel.: 34-91-585-4607; Fax: 34-91-585-4606; E-mail: jclacal{at}iib.uam.es.

    ABBREVIATIONS

The abbreviations used are: SRE, serum response element; SRF, serum response factor; TCF, ternary complex factor; LPA, lysophosphatidic acid; NF-kappa B, nuclear factor-kappa B; DMEM, Dulbecco's modified Eagle's medium; HIV, human immunodeficiency virus; CAT, chloramphenicol acetyltransferase; beta -gal, beta -galactosidase; PAGE, polyacrylamide gel electrophoresis; CMV, cytomegalovirus.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Perona, R., Montaner, S., Saniger, L., Sánchez-Pérez, I., Bravo, R., and Lacal, J. C. (1997) Genes Dev. 11, 463-475[Abstract]
  2. Treisman, R. (1994) Curr. Opin. Genet. Dev. 4, 96-101[Medline] [Order article via Infotrieve]
  3. Mueller, C. G. F., and Nordheim, A. (1991) EMBO J. 10, 4219-4229[Abstract]
  4. Janknecht, R., and Nordheim, A. (1992) Nucleic Acids Res. 20, 3317-3324[Abstract]
  5. Dalton, S., and Treisman, R. (1992) Cell 68, 597-612[Medline] [Order article via Infotrieve]
  6. Shaw, P. E. (1992) EMBO J. 11, 3011-3019[Abstract]
  7. Treisman, R., Marais, R., and Wynne, J. (1992) EMBO J. 11, 4631-4640[Abstract]
  8. Shore, P., and Sharrocks, A. D. (1994) Mol. Cell. Biol. 14, 3283-3291[Abstract]
  9. Johansen, F.-E., and Prywes, R. (1995) Biochem. Biophys. Acta 1242, 1-10[CrossRef][Medline] [Order article via Infotrieve]
  10. Gille, H., Sharrocks, A. D., and Shaw, P. E. (1992) Nature 358, 414-417[CrossRef][Medline] [Order article via Infotrieve]
  11. Marais, R., Wynne, J., and Treisman, R. (1993) Cell 73, 381-393[Medline] [Order article via Infotrieve]
  12. Janknecht, R., Ernst, W. H., Pingoud, V., and Nordheim, A. (1993) EMBO J. 12, 5097-5104[Abstract]
  13. Kortenjann, M., Thornae, O., and Shaw, P. E. (1994) Mol. Cell. Biol. 14, 4815-4824[Abstract]
  14. Gille, H., Kortenjann, M., Thomae, O., Moomaw, C., Slaughter, C., Cobb, M. H., and Shaw, P. E. (1995) EMBO J. 14, 951-962[Abstract]
  15. Whitmarsh, A. J., Shore, P., Sharrocks, A. D., and Davis, R. J. (1995) Science 269, 403-407[Medline] [Order article via Infotrieve]
  16. Whitmarsh, A. J., Yang, S.-H., Su, M. S.-S., Sharrocks, A. D., and Davis, R. J. (1997) Mol. Cell. Biol. 17, 2360-2371[Abstract]
  17. Janknecht, R., and Hunter, T. (1997) EMBO J. 16, 1620-1627[Abstract/Free Full Text]
  18. Hill, C. S., Wynne, J., and Treisman, R. (1995) Cell 81, 1159-1170[Medline] [Order article via Infotrieve]
  19. Fromm, C., Coso, O. A., Montaner, S., Xu, N., and Gutkind, J. S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10098-10103[Abstract/Free Full Text]
  20. Kim, B.-C., and Kim, J.-H. (1997) FEBS Lett. 407, 7-12[CrossRef][Medline] [Order article via Infotrieve]
  21. Kim, J.-H., Kwack, H.-J., Choi, S.-E., Kim, B.-C., Kim, Y.-S., Kang, I.-J., and Kumar, C. C. (1997) FEBS Lett. 496, 93-96
  22. Kim, B. C., Lim, C.-J., and Kim, J.-H. (1997) FEBS Lett. 415, 325-328[CrossRef][Medline] [Order article via Infotrieve]
  23. Johansen, F.-E., and Prywes, R. (1994) Mol. Cell. Biol. 14, 5920-5928[Abstract]
  24. Hill, C. S., Wynne, J., and Treisman, R. (1994) EMBO J. 13, 5421-5432[Abstract]
  25. Johansen, F.-E., and Prywes, R. (1993) Mol. Cell. Biol. 13, 4640-4647[Abstract]
  26. Montaner, S., Perona, R., Saniger, L., and Lacal, J. C. (1998) J. Biol. Chem. 273, 12779-12785[Abstract/Free Full Text]
  27. Miyamoto, S., and Verma, I. M. (1995) Adv. Cancer Res. 66, 255-292[Medline] [Order article via Infotrieve]
  28. Verma, I. M., Stevenson, J. K., Schwarz, E. M., van Antwerp, D., and Miyamoto, S. (1995) Genes Dev. 9, 2723-2735[CrossRef][Medline] [Order article via Infotrieve]
  29. Baldwin, A. S., Jr. (1996) Annu. Rev. Immunol. 14, 649-691[CrossRef][Medline] [Order article via Infotrieve]
  30. Baldwin, A. S., Jr., Azizkhan, J. C., Jensen, D. E., Beg, A. A., and Coodly, L. R. (1991) Mol. Cell. Biol. 11, 4943-4951[Medline] [Order article via Infotrieve]
  31. Abbadie, C., Kabrun, N., Bouali, F., Smardova, J., Stéhelin, D., Vandenbunder, B., and Enrietto, P. J. (1993) Cell 75, 899-912[Medline] [Order article via Infotrieve]
  32. Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S., and Baltimore, D. (1995) Nature 376, 167-170[CrossRef][Medline] [Order article via Infotrieve]
  33. Beg, A. A., and Baltimore, D. (1996) Science 274, 782-784[Abstract/Free Full Text]
  34. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789[Abstract/Free Full Text]
  35. Wang, C.-Y., Mayo, M. W., and Baldwin, A. S., Jr. (1996) Science 274, 784-787[Abstract/Free Full Text]
  36. Grimm, S., Bauer, M. K. A., Baeuerle, P. A., and Schulze-Osthoff, K. (1996) J. Cell Biol. 134, 13-23[Abstract]
  37. Grilli, M., Pizzi, M., Mermo, M., and Spano, P. (1996) Science 274, 1383-1385[Abstract/Free Full Text]
  38. Wu, M., Arsura, M., Bellas, R. E., Fitzgerald, M. J., Lee, H., Schauer, S. L., Sherr, D. H., and Sonenshein, G. E. (1996) Mol. Cell. Biol. 16, 5015-5025[Abstract]
  39. Wu, M., Lee, H., Bellas, R. E., Schauer, S. L., Arsura, M., Katz, D., Fitzgerald, M. J., Rothstein, T. L., Sherr, D. H., and Sonenshein, G. E. (1996) EMBO J. 17, 4682-4690
  40. Liu, Z., Hsu, H., Goeddel, D. V., and Karin, M. (1996) Cell 87, 565-576[Medline] [Order article via Infotrieve]
  41. Bash, J., Zong, W.-X., and Gélinas, C. (1997) Mol. Cell. Biol. 17, 6526-6536[Abstract]
  42. Franzoso, G., Carlson, L., Brown, K., Daucher, M. B., Bressler, P., and Siebenlist, U. (1996) EMBO J. 15, 3403-3412[Abstract]
  43. Sealy, L., Malone, D., and Pawlak, M. (1997) Mol. Cell. Biol. 17, 1744-1755[Abstract]
  44. Perona, R., Esteve, P., Jiménez, B., Ballestero, R. P., Ramón y Cajal, S., and Lacal, J. C. (1993) Oncogene 8, 1285-1292[Medline] [Order article via Infotrieve]
  45. Coso, O. A., Chiariello, M., Yu, J.-C., Teramoto, H., Crespo, P., Xu, N., Miki, T., and Gutkind, J. S. (1995) Cell 81, 1137-1146[Medline] [Order article via Infotrieve]
  46. Nabel, G., and Baltimore, D. (1987) Nature 326, 711-713[CrossRef][Medline] [Order article via Infotrieve]
  47. Devary, Y., Rosette, C., DiDonato, J. A., and Karin, M. (1993) Science 261, 1442-1445[Medline] [Order article via Infotrieve]
  48. Descombes, P., and Schibler, U. (1991) Cell 67, 569-579[Medline] [Order article via Infotrieve]
  49. Coppola, J., Bryant, S., Koda, T., Conway, D., and Barbacid, M. (1991) Cell Growth Differ. 2, 95-105[Abstract]
  50. Horii, Y., Beeler, J. F., Sakaguchi, K., Tachibana, M., and Miki, T. (1994) EMBO J. 13, 4776-4786[Abstract]
  51. del Peso, L., Lucas, L., Esteve, P., and Lacal, J. C. (1997) Biochem. J. 322, 519-528[Medline] [Order article via Infotrieve]
  52. Whiteside, S. T., Ernst, M. K., LeBail, O., Laurent-Winter, C., Rice, N., and Israël, A. (1995) Mol. Cell. Biol. 15, 5339-5345[Abstract]
  53. Gorman, C. M., Moffat, L. F., and Howard, B. H. (1982) Mol. Cell. Biol. 2, 1044-1051[Medline] [Order article via Infotrieve]
  54. König, H., Ponta, H., Rahmsdorf, U., Büscher, M., Schönthal, A., Rahmsdorf, H. J., and Herrlich, P. (1989) EMBO J. 8, 2559-2566[Abstract]
  55. Cerione, R. A., and Zheng, Y. (1996) Curr. Opin. Cell Biol. 8, 216-222[CrossRef][Medline] [Order article via Infotrieve]
  56. Alberts, A. S., Geneste, O., and Treisman, R. (1998) Cell 92, 475-487[Medline] [Order article via Infotrieve]
  57. LeClair, K. P., Blanar, M. A., and Sharp, P. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8145-8149[Abstract]
  58. Perkins, N. D., Edwards, N. L., Duckett, C. S., Agranoff, A. B., Schmid, R. M., and Nabel, G. J. (1993) EMBO J. 12, 3551-3558[Abstract]
  59. Stein, B., Cogswell, P. C., and Baldwin, A. S., Jr. (1993) Mol. Cell. Biol. 13, 3964-3974[Abstract]
  60. Stein, B., Baldwin, A. S., Jr., Ballard, D. W., Greene, W. C., Angel, P., and Herrlich, P. (1993) EMBO J. 12, 3879-3891[Abstract]
  61. Kaszubska, W., Hooft van Huijsduijnen, R., Ghersa, P., DeRaemy-Schenk, A.-M., Chen, B. P. C., Hai, T., DeLamarter, J. F., and Whelan, J. (1993) Mol. Cell. Biol. 13, 7180-7190[Abstract]
  62. Xu, X., Prorock, C., Ishikawa, H., Maldonado, E., Ito, Y., and Gélinas, C. (1993) Mol. Cell. Biol. 13, 6733-6741[Abstract]
  63. Kerr, L. D., Ransone, L. J., Wamsley, P., Schmitt, M. J., Boyer, T. G., Zhou, Q., Berk, A., and Verma, I. M. (1993) Nature 365, 412-419[CrossRef][Medline] [Order article via Infotrieve]
  64. Scheinman, R. I., Gualberto, A., Jewell, C. M., Cidlowski, J. A., and Baldwin, A. S., Jr. (1995) Mol. Cell. Biol. 15, 943-953[Abstract]
  65. Shen, C.-H., and Stavnezer, J. (1998) Mol. Cell. Biol. 18, 3395-3404[Abstract/Free Full Text]
  66. Hirano, F., Tanaka, H., Hirano, Y., Hiramoto, M., Handa, H., Makino, I., and Scheidereit, C. (1998) Mol. Cell. Biol. 18, 1266-1274[Abstract/Free Full Text]
  67. Kuang, A. A., Novak, K. D., Kang, S.-M., Bruhn, K., and Lenardo, M. J. (1993) Mol. Cell. Biol. 13, 2536-2545[Abstract]
  68. Stein, B., and Yang, M. X. (1995) Mol. Cell. Biol. 15, 4971-4979[Abstract]
  69. Brown, K., Gerstberger, S., Carlson, L., Franzoso, G., and Siebenlist, U. (1995) Science 267, 1485-1488[Medline] [Order article via Infotrieve]
  70. Traenckner, E. B.-M., Pahl, H. L., Henkel, T., Schmidt, K. N., Wilk, S., and Baeuerle, P. A. (1995) EMBO J. 14, 2876-2883[Abstract]
  71. Brockman, J. A., Scherer, D. C., McKinsey, T. A., Hall, S. M., Qi, X., Lee, W. Y., and Ballard, D. W. (1995) Mol. Cell. Biol. 15, 2809-2818[Abstract]
  72. Chen, Z. J., Hagler, J., Palombella, V. J., Melandri, F., Scherer, D., Ballard, D., and Maniatis, T. (1995) Genes Dev. 9, 1586-1597[Abstract]
  73. Baldi, L., Brown, K., Franzoso, G., and Siebenlist, U. (1996) J. Biol. Chem. 271, 376-379[Abstract/Free Full Text]
  74. van Aelst, L., and D'Souza-Schorey, C. (1997) Genes Dev. 11, 2295-2322[Free Full Text]
  75. Kim, J.-H., Cho, Y.-S., Kim, B.-C., Kim, Y.-S., and Lee, G.-S. (1997) Biochem. Biophys. Res. Commun. 232, 223-226[CrossRef][Medline] [Order article via Infotrieve]
  76. Metz, R., and Ziff, E. (1991) Genes Dev. 5, 1754-1766[Abstract]
  77. Metz, R., and Ziff, E. (1991) Oncogene 6, 2165-2178[Medline] [Order article via Infotrieve]
  78. Williams, S. C., Cantwell, C. A., and Johnson, P. F. (1991) Genes Dev. 5, 1553-1567[Abstract]
  79. Johnson, P., and Williams, S. C. (1994) in Liver Gene Expression (Yaniv, M., and Tronche, F., eds), pp. 231-258, R. G. Landes Co., Austin, TX
  80. Diehl, J. A., and Hannink, M. (1994) Mol. Cell. Biol. 14, 6635-6646[Abstract]
  81. Zhang, Y., Broser, M., and Rom, W. N. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2225-2229[Abstract]
  82. Ruocco, M. R., Chen, X., Ambrosino, C., Dragonetti, E., Liu, W., Mallardo, M., De Falco, G., Palmieri, C., Franzoso, G., Quinto, I., Venuta, S., and Scala, G. (1996) J. Biol. Chem. 271, 22479-22486[Abstract/Free Full Text]
  83. Plevy, S. E., Gemberling, J. H. M., Hsu, S., Dorner, A. J., and Smale, S. T. (1997) Mol. Cell. Biol. 17, 4572-4588[Abstract]
  84. Xia, C., Cheshire, J. K., Patel, H., and Woo, P. (1997) Int. J. Biochem. Biol. 29, 1525-1539[CrossRef]
  85. Cao, Z., Umek, R. M., and McKnight, S. L. (1991) Genes Dev. 5, 1538-1552[Abstract]
  86. Yeh, W.-C., Cao, Z., Classon, M., and McKnight, S. L. (1995) Genes Dev. 9, 168-181[Abstract]
  87. Niehof, M., Manns, M. P., and Trautwein, C. (1997) Mol. Cell. Biol. 17, 3600-3613[Abstract]
  88. Wegner, M., Cao, Z., and Rosenfeld, M. G. (1992) Science 256, 370-373[Medline] [Order article via Infotrieve]
  89. Nakajima, T., Kinoshita, S., Sasagawa, T., Sasaki, K., Naruto, M., Kishimoto, T., and Akira, S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2207-2211[Abstract]
  90. Trautwein, C., Caelles, C., van der Geer, P., Hunter, T., Karin, M., and Chojkier, M. (1993) Nature 364, 544-547[CrossRef][Medline] [Order article via Infotrieve]
  91. Jähner, D., and Hunter, T. (1991) Mol. Cell. Biol. 11, 3682-3690[Medline] [Order article via Infotrieve]
  92. Jiménez, B., Arends, M., Esteve, P., Perona, R., Sánchez, R., Ramón y Cajal, S., Wyllie, A., and Lacal, J. C. (1995) Oncogene 10, 811-816[Medline] [Order article via Infotrieve]
  93. Esteve, P., del Peso, L., and Lacal, J. C. (1995) Oncogene 11, 2657-2665[Medline] [Order article via Infotrieve]
  94. Qiu, R.-G., Chen, J., Kirn, D., McCormick, F., and Symons, M. (1995) Nature 374, 457-459[CrossRef][Medline] [Order article via Infotrieve]
  95. Prendergast, G. C., Khosravi-Far, R., Solski, P. A., Kurzawa, H., Lebowitz, P. F., and Der, C. J. (1995) Oncogene 10, 2289-2296[Medline] [Order article via Infotrieve]
  96. Khosravi-Far, R., Solski, P. A., Clark, G. J., Kinch, M. S., and Der, C. J. (1995) Mol. Cell. Biol. 15, 6443-6453[Abstract]
  97. Minden, A., Lin, A., Claret, F. X., Abo, A., and Karin, M. (1995) Cell 81, 1147-1157[Medline] [Order article via Infotrieve]
  98. Fritz, G., Kaina, B., and Aktories, K. (1995) J. Biol. Chem. 270, 25172-25177[Abstract/Free Full Text]
  99. Narumiya, S. (1996) J. Biochem. (Tokyo) 120, 215-228[Abstract]
  100. Luo, L., Hensch, T. K., Ackerman, L., Barbel, S., Jan, L. Y., and Jan, Y. N. (1996) Nature 379, 837-840[CrossRef][Medline] [Order article via Infotrieve]
  101. Qiu, R.-G., Abo, A., McCormick, F., and Symons, M. (1997) Mol. Cell. Biol. 17, 3449-3458[Abstract]
  102. Henning, S. W., Galandrini, R., Hall, A., and Cantrell, D. A. (1997) EMBO J. 16, 2397-2407[Abstract/Free Full Text]
  103. del Peso, L., Hernández-Alcoceba, R., Embade, N., Carnero, A., Esteve, P., Paje, C., and Lacal, J. C. (1997) Oncogene 15, 3047-3057[CrossRef][Medline] [Order article via Infotrieve]
  104. Ruben, S. M., Narayanan, R., Klement, J. F., Chen, C.-H., and Rosen, C. A. (1992) Mol. Cell. Biol. 12, 444-454[Abstract]
  105. Matsusaka, T., Fujikawa, K., Nishio, Y., Mukaida, N., Matsushima, K., Kishimoto, T., and Akira, S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10193-10197[Abstract]
  106. Sears, R. C., and Sealy, L. (1994) Mol. Cell. Biol. 14, 4855-4871[Abstract]
  107. van Corven, E. J., Groenink, A., Jalink, K., Eichholtz, T., and Moolenaar, W. H. (1989) Cell 59, 45-54[Medline] [Order article via Infotrieve]
  108. Chen, C.-Y., Del Gatto-Konczak, F., Wu, Z., and Karin, M. (1998) Science 280, 1945-1949[Abstract/Free Full Text]
  109. Perkins, N. D., Felzien, L. K., Betts, J. C., Leung, K., Beach, D. H., and Nabel, G. J. (1997) Science 275, 523-527[Abstract/Free Full Text]
  110. Mink, S., Haenig, B., and Klempnauer, K.-H. (1997) Mol. Cell. Biol. 17, 6609-6617[Abstract]
  111. Gerritsen, M. E., Williams, A. J., Neish, A. S., Moore, S., Shi, Y., and Collins, T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2927-2932[Abstract/Free Full Text]
  112. Ramirez, S., Ait Si Ali, S., Robin, P., Trouche, D., and Harel-Bellan, A. (1997) J. Biol. Chem 272, 31016-31021[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.